Patents by Inventor Andrew William Gibson

Andrew William Gibson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PREPARATIONS THEREOF
    Publication number: 20210154221
    Abstract: The present invention is directed to 4?-substituted nucleoside derivatives of Formula I and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS and/or ARC. The present invention also provides processes for the preparation of 4?-substituted nucleoside derivatives of Formula I and derivatives thereof.
    Type: Application
    Filed: February 3, 2021
    Publication date: May 27, 2021
    Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme Limited
    Inventors: Mark McLaughlin, Edward Cleator, Jongrock Kong, Andrew William Gibson, David R. Lieberman, Alejandro Diequez Vazquez, Stephen Philip Keen, Michael J. Williams, Jeffrey C. Moore, Erika M. Milczek, Feng Peng, Kevin M. Belyk, Zhiguo Jake Song
  • 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PREPARATIONS THEREOF
    Publication number: 20190022115
    Abstract: The present invention is directed to 4?-substituted nucleoside derivatives of Formula (I) and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS and/or ARC. The present invention also provides processes for the preparation of 4?-substituted nucleoside derivatives of Formula (I) and derivatives thereof.
    Type: Application
    Filed: September 16, 2016
    Publication date: January 24, 2019
    Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme Limited
    Inventors: Vinay M. Girijavallabhan, Mark McLaughlin, Edward Cleator, Jongrock Kong, Andrew William Gibson, David R. Lieberman, Alejandro Dieguez Vazquez, Stephen Philip Keen, Michael J. Williams, Jeffrey C. Moore, Erika M. Milczek, Feng Peng, Kevin M. Belyk, Zhiguo Jake Song
  • Pyrazolo 1,5 a benzimidazole photographic color couplers
    Patent number: 5876912
    Abstract: Novel non-diffusible pyrazolo-?1,5-a! benzimidazole color couplers having an alkylene-, oxyalkylene- or arylene- thio coupling-off group, substituted with a carboxylic acid or dialkylamino group, have dye-forming and/or bleach-accelerating properties. The couplers are generally associated with a silver halide emulsion layer coated on a support to form a single color or multi-color photographic element.
    Type: Grant
    Filed: April 27, 1995
    Date of Patent: March 2, 1999
    Assignee: Eastman Kodak Company
    Inventors: Michael William Crawley, Andrew William Gibson, Paul Louis Reginald Stanley, Hugh Martin Williamson
  • Phenol substituted pyrazolo 1, 5-a benzimidazole couplers
    Patent number: 5776669
    Abstract: The invention provides a pyrazolo?1,5-a!benzimidazole compound of the formula (I) ##STR1## wherein R to R.sup.4 are selected from H, substituted or unsubstituted alkoxy, anilino, aryl, alkyl or amido groups, and X is H or a coupling-off group; characterized in that said compound of Formula I is linked via any of the moieties R to R.sup.4 or X to a compound of the formula (II): ##STR2## wherein W is an electron withdrawing group and L is a linking group. Compounds with the low pKa phenolic substituent provide improved coupling activity when used with a photographic element and improved contrast.
    Type: Grant
    Filed: February 11, 1997
    Date of Patent: July 7, 1998
    Assignee: Eastman Kodak Company
    Inventors: Michael William Crawley, Andrew William Gibson, Hugh Martin Williamson
  • Chemical synthesis of a chiral oxazinone
    Patent number: 5668280
    Abstract: The present invention provides a process for the preparation of substantially pure N-benzyl-3-(S)-(4-fluorophenyl)-1,4-oxazin-2-one which comprises:(i) contacting racemic N-benzyl-3-(4-fluorophenyl)-1,4-oxazin-2-one with (-)-3-bromocamphor-8-sulphonic acid (hereinafter referred to as (-)-3-BCS) in the presence of a racemising agent;(ii) collecting the resultant crystalline (-)-3-BCS salt of N-benzyl-3-(S)-(4-fluorophenyl)-1,4-oxazin-2-one; and(iii) liberating the free base of N-benzyl-3-(S)-(4-fluorophenyl)-1,4-oxazin-2-one by treatment of the (-)-3-BCS salt collected in step (ii) with aqueous base.
    Type: Grant
    Filed: May 23, 1996
    Date of Patent: September 16, 1997
    Assignee: Merck Sharp & Dohme Limited
    Inventors: Ramon John Alabaster, Ian Frank Cottrell, Andrew William Gibson, Simon Adrian Johnson